← Reviews
Jul 19, 2026

Oral Microbial and Metabolic Alterations in Patients With Oral Lichen Planus Concomitant With Type 2 Diabetes Mellitus

Patients with co-occurring oral lichen planus and type 2 diabetes show reduced salivary alpha diversity, elevated Pseudomonas, and a distinct metabolic profile compared to controls and OLP-only patients.

Evidence levelDNarrative / animal / in vitro / mechanistic
Study typeobservational
Sample60
Effect directionInsufficient
CertaintyVery low
Clinical applicabilityVery low
Overinterpretation risk1/5 · Low
PECO
Population
Exposure
Comparator
Outcome

What the study showed

Alpha diversity (Chao1) was significantly lower in both disease groups versus controls; beta diversity showed no clear group separation. Pseudomonas abundance was elevated in the OLP+DM group and positively correlated with lesion severity. Limonin was decreased while thymine and epinephrine were increased in OLP+DM, correlating with severity and pain scores.

How it was done

Cross-sectional observational study with 60 participants (20 controls, 20 OLP, 20 OLP+DM); salivary samples analyzed by 16S rRNA sequencing and untargeted metabolomics; associations assessed by Spearman correlation.

Risk of bias

Cross-sectional design precludes causal inference. Groups of only 20 participants each provide limited statistical power; the abstract does not report adjustment for confounders such as antidiabetic or anti-inflammatory medications.

Interpretation limit

What this study does NOT prove

The study does not prove that oral dysbiosis or metabolic alterations cause or worsen oral lichen planus in the context of diabetes.

In clinical practice

Findings are exploratory and do not support changes to current clinical management. Observational correlations between microbial/metabolic features and disease severity require validation in larger, longitudinal studies.

Limitations

Cross-sectional design precludes causal inference. Groups of only 20 participants each provide limited statistical power; the abstract does not report adjustment for confounders such as antidiabetic or anti-inflammatory medications.

Technical appendix

Version history

  • 1.0 · 2026-07-19 — Auto-generated under Evidence Standard v1.0
Source: DOI 10.1002/mbo3.70361 · 2026

Paid access: structured summary from public metadata; consult the original study at the source.

Microbiota Weekly

The week in microbiota evidence, in your language. Structured summaries, traceable to the source.